Insulin Delivery Devices Market Size, Share & Trends Analysis

Insulin Delivery Devices Market Size, Share & Trends Analysis

2022-10-12 12:10:17 Return to List

Insulin Delivery Devices Market Size, Share & Trends Analysis 

The global insulin delivery devices market size was valued at USD 12.5 billion in 2021 and is anticipated to expand at a compound annual growth rate (CAGR) of 7.4% from 2022 to 2030. Insulin delivery devices including syringes, insulin pens, pumps, and jet injectors are used to deliver insulin to diabetic patients. One of the foremost factors contributing to the growth of the market is the surging number of diabetics due to aging, obesity, and unhealthy lifestyles. Obesity is believed to be a major factor leading to the development of diabetes in individuals. According to the WHO, in 2014, over 1.9 billion people were identified to be overweight, of which, around 600 million people were obese.

Risk factors, such as obesity and being overweight are highly linked to the incidence of diabetes, which is rising by epidemic proportions, thus rendering a high prevalence of diabetes. Consequently, the large population afflicted with diabetes is driving the market for insulin delivery devices. In addition, the high demand for advanced insulin delivery devices is supporting the adoption of recently launched innovative pen devices and portable pumps, which is estimated to boost the market growth. However, stringent government rules and regulations governing the product approval process and the high cost of insulin analogs in diabetes care management could hinder the market growth.

The outbreak of COVID-19 led to dramatic turmoil in the market for insulin delivery devices. Nearly 40% of the global Covid 19 facilities reported the admissions of people with diabetes. However, ~45% of those patients, didn’t receive routine medical care due to the fear of the virus spreading. One in every 5 patients, experienced the reduced availability of blood glucose monitoring devices and ~20% experienced the delaying of refilling of insulin pumps, mainly due to financial constraints. Disruption in the supply chain due to closure of manufacturing sites, shipping delays or shutdowns, and trade limitations or export bans on life-saving drugs such as Insulin.

But, the lack of reimbursement from the government, insurance losses, economic setbacks experienced by buyers, and the high cost of insulin, have led to the decline in the market for insulin delivery devices. It is said to grow at a steady rate by mid-2022.